Synopsis:
BOFA Securities bought 274,031 shares of Dr. Agarwals from Morgan Stanley in a ₹11.95 crore block deal, signaling institutional interest.
This small-cap healthcare stock, engaged in providing advanced eye care services, performing surgeries, and offering optical products and treatments across a wide patient base in India, jumped 3 percent after 2.74 lakh shares were exchanged between BOFA Securities and Morgan Stanley through a block deal.
With a market capitalization of Rs. 13,526.84 crores, the share of Dr Agarwals 1Health Care Limited has reached an intraday high of Rs. 440 per equity share on NSE, rising nearly 3 percent from its previous day’s close price of Rs. 427.25. Since then, the stock has retreated and is currently trading at Rs. 427.85 per equity share.
On 11th July 2025, a block deal took place in Dr. Agarwals Health Care Limited on the NSE, where BOFA Securities Europe SA purchased 274,031 shares at an average price of Rs. 436 per share.
At the same time, Morgan Stanley Asia Singapore PTE sold the exact quantity at the same price. The total deal value amounted to approximately Rs. 11.95 crore. This large transaction between two major institutional investors reflects notable interest in the stock at that price level.
Dr. Agarwal’s Health Care Limited is a leading eye care service provider in India, recognized as the country’s largest eye care service chain with a 25 percent market share. The company was incorporated in 2010 and has rapidly expanded its footprint, operating over 240 hospitals in India and a global network of more than 250 hospitals.
The company offers a full range of eye care services, including surgeries like cataract, LASIK, and SMILE, along with treatment for glaucoma, diabetic eye issues, and more. They also provide eye check-ups and non-surgical treatments and sell optical products, contact lenses, and eye-related medicines under one roof.
Dr. Agarwals Health Care Limited employs over 800 expert ophthalmologists and performs more than 200,000 eye surgeries each year. The company serves over 2 million patients across India, making it one of the leading eye care providers in the country with a strong presence and trusted reputation.
Coming into financial highlights, Dr Agarwals Health Care Limited’s revenue has increased from Rs. 349 crore in Q4 FY24 to Rs. 460 crore in Q4 FY25, which has grown by 31.81 percent. The net profit has also grown by 4.88 percent from Rs. 41 crore in Q4 FY24 to Rs. 43 crore in Q4 FY25. Dr Agarwals Health Care Limited’s revenue and net profit have grown at a CAGR of 34.96 percent and 36.76 percent, respectively, over the last three years.
In terms of return ratios, the company’s ROCE and ROE stand at 10.4 percent and 5.30 percent, respectively. Dr Agarwals Health Care Limited has an earnings per share (EPS) of Rs. 2.64, and its debt-to-equity ratio is 0.51x.
Written By – Nikhil Naik
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
